The global Migraine Drugs market size is expected to be worth around US$ 10.8 billion by 2030, according to a new report by Vision Research Reports.
The global Migraine Drugs market size was valued at US$ 2.7 billion in 2020 and is anticipated to grow at a CAGR of 28.0% during forecast period 2021 to 2030.
The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.
Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.
Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.
Majority of the drugs currently available are approved for the acute form of the condition, led by generic triptans as the first-line treatment. The market is witnessing a shift in terms of strong R&D with the introduction of CGRP-based therapies and uptake of novel drug classes such as ditans, gepants, and reformulation of triptans for both chronic and episodic migraine.
The market can be segmented by treatment into acute/abortive treatment and preventive/ prophylactic treatment. Acute treatment includes therapeutic classes such as triptans, ergot alkaloids, NSAIDs, and other non-specific drugs prescribed over-the-counter (OTC) such as aspirin, acetaminophen, and ibuprofen. The therapeutic classes are diversified through the route of administration with drugs available as oral, injectables, nasal spray, and others.
Preventive/prophylactic treatment includes prescription of off-label and generic medications including beta-blockers such as atenolol and propranolol, anti-epileptics such as topiramate, and divalproex sodium. Currently, Allergan’s Botox (neurotoxin), Amgen/ Novartis’s Aimovig, and Teva’s Ajovy (CGRP mAb) are the only drugs approved for migraine prevention. However, Botox requires more than 30 injections across the forehead, shoulders, and neck and does not provide relief from episodic migraine.
Current research focuses on using novel mechanisms of action such as CGRP-based receptor and ligand inhibition, corticotrophin receptor antagonism, and nitrous oxide inhibition. Approval of CGRP monoclonal antibodies is one of the key developments in the preventive market. Though several companies are expected to enter this sphere in the next two years, Amgen and Novartis are poised to benefit from Aimovig’s first-mover status, favorable reimbursement scenario, and easy to use the pen-device mode of administration.
The migraine drugs market is witnessing intense pipeline activity, with six product candidates in late-stage clinical development. Shift from standard symptomatic therapies to novel disease-specific treatments is evident in the R&D pipeline as the majority of drug candidates target unmet needs in migraine therapeutics.
Currently, there are three novel drugs in the late-stage pipeline that are set to change the treatment landscape. These drugs follow disease-modifying approaches and are associated with superior clinical efficacy and a favorable safety profile compared to currently marketed drugs.
Allergan’s ubrogepant and Eli Lilly’s Lasmiditan are expected to be first-in-class migraine drugs with a novel mechanism of actions for patients unresponsive to triptans or those who are at risk of cardiovascular disorders. Several triptans under late-stage development consist of reformulation of generic triptans, with an aim to improve the efficacy of existing formulations. Zosano Pharma’s M207 is being investigated in the Phase III ADAM (NCT03282227) trial. The drug is a novel formulation of zolmitriptan delivered via Zosano’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology.
Migraine is the third most prevalent and the sixth most disabling illness in the world, affecting more than 37 million in the U.S. and over one billion people worldwide. The U.S. dominated the market with more than 65% share in 2020 and is projected to maintain its position until 2025. Launch of CGRP based therapies, high prevalence, increasing adoption of novel therapeutics, and a large target population in the U.S. are some of the factors contributing to the dominance of the country.
Pfizer, GlaxoSmithKline, Allergan, Amgen, Eli Lilly, Teva Pharma, Biohaven Pharma, Johnson & Johnson, and Valeant Pharma
Treatment Class Outlook
Acute / Abortive Treatment
Preventive/ Prophylactic Treatment
Therapeutic Class Outlook
Acetylcholine Inhibitors/ neurotoxins
CGRP small molecule antagonists
CGRP monoclonal antibodies
Route of Administration Outlook
The Migraine Drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Migraine Drugs market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Migraine Drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Migraine Drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Migraine Drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Migraine Drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Migraine Drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Migraine Drugs market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Migraine Drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Migraine Drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Migraine Drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Migraine Drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Migraine Drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Migraine Drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Migraine Drugs market. These factors have benefited the growth of the global market for Migraine Drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Migraine Drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Migraine Drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Cardiac Resynchronization Therapy Market (By Product: CRT-Defibrillator, CRT-Pacemaker; By End-user: Hospital, Cardiac Center) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
X-ray systems Market (By Modality: Radiography, Fluoroscopy, Mammography; By Technology: Digital Radiography, Computed Radiography; By Mobility: Stationary, Mobile; By End-use: Hospitals, Diagnostic imaging centres) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
eClinical Solutions Market (By Product: Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS), Clinical Data Integration Platforms, Electronic Clinical Outcome Assessment (eCOA), Safety Solutions, Electronic Trial Master File (eTMF); By Delivery Mode: Web-hosted (On demand), Licensed Enterprise (On premise), Cloud-based; By Development Phase: Phase I, Phase II, Phase III, Phase IV; By End-use: Hospitals/Healthcare providers, CROs, Academic Institutes, Pharma & Biotech Organizations, Medical Device Manufacturers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Fitness App Market (By Product: Exercise & Weight Loss, Diet & Nutrition, Activity Tracking; By Platform: Android, iOS; By Device : Smartphones, Tablets, Wearable Devices) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...
Cannabis Pharmaceuticals Market (By Brand Type: Sativex, Epidiolex) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2022 – 2030Read more...